Essex Property Trust, Inc. vs Nuwellis Inc — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.15B), while Nuwellis Inc trades at $1.48 (market cap $542.80K). The key difference: Essex Property Trust, Inc. is far larger — about 33437.7× Nuwellis Inc's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| ESS | NUWE | |
|---|---|---|
Market Cap | $18.15B | $542.80K |
Sector | Real Estate | Technology |
52-Week High | $298.33 | $220.50 |
52-Week Low | $239.61 | $1.42 |
Enterprise Value | $24.75B | -$1.27M |
Dividend Yield | 3.93% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Trailing returns across standard periods
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →